Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

OBJECTIVE: Preclinical data suggest that linagliptin, a dipeptidyl peptidase-4 inhibitor, may lower urinary albumin excretion. The ability of linagliptin to lower albuminuria on top of renin-angiotensin-aldosterone system (RAAS) inhibition in humans was analyzed by pooling data from four similarly d...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Groop, Per-Henrik, Cooper, Mark E., Perkovic, Vlado, Emser, Angela, Woerle, Hans-Juergen, von Eynatten, Maximilian
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2013
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3816860/
https://ncbi.nlm.nih.gov/pubmed/24026560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc13-0323
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky